Every breakthrough therapy begins with groundbreaking science. But bringing that science from the laboratory to patients requires something equally important. A manufacturing process that is reliable, compliant, and built on trusted data.
For one of Japan’s leading academic research centres, that challenge became increasingly urgent. As the organisation prepared to manufacture viral vectors for next-generation gene and cell therapies, it faced the reality shared by many research institutions: sophisticated science supported by paper-based manufacturing records, limited digital infrastructure, and a team with little experience implementing GMP-compliant manufacturing systems.
At the same time, expectations were rising. Regulatory requirements demanded stronger data integrity, greater traceability, and manufacturing processes capable of supporting future clinical and commercial production. With a government-funded programme operating under strict timelines, there was little room for delay.
The organisation needed more than software. It needed a practical path to digital manufacturing.
Working together with BatchLine, the team transformed paper-based batch records into a compliant Electronic Batch Record (EBR) platform, laying the foundation for a modern, data-driven manufacturing environment. More importantly, they demonstrated that digital transformation is achievable even for organisations with limited resources and no prior experience with GMP digital systems.
Today, that foundation is helping accelerate advanced therapy manufacturing while preparing the organisation for the next stage of its journey.
About the Organisation
The organisation is one of Japan’s leading translational research centres, dedicated to bridging scientific discovery with clinical application.
Working alongside universities, biotechnology companies, and government-funded programmes, the centre develops manufacturing capabilities for advanced therapies including adeno-associated virus (AAV), lentiviral vectors, and cell and gene therapies.
Its mission extends beyond research. By creating sustainable GMP manufacturing capabilities, the organisation is helping ensure that promising therapies can move efficiently from the laboratory into clinical use and ultimately to the patients who need them.
The Turning Point
As manufacturing programmes expanded, so did the complexity of documentation.
Every production run generated hundreds of pages of records. Operators manually completed batch documentation, reviewers checked information line by line, and quality teams faced increasing pressure to maintain data integrity while preparing for future inspections.
For a research organisation operating with lean resources, the process was becoming unsustainable.
Adding to the challenge, the internal team had little experience implementing GMP-compliant digital systems or Computerised System Validation (CSV). Yet within a government-funded programme, they were expected to establish a compliant manufacturing environment within an ambitious timeline.
The question was no longer whether digitalisation was necessary.
It was how to achieve it without disrupting ongoing research or introducing unnecessary complexity.
Choosing a Different Approach
Rather than pursuing a large, traditional Manufacturing Execution System (MES) project, the organisation looked for a solution that could evolve alongside its manufacturing maturity.
BatchLine stood out for its practical approach.
Its cloud-based architecture, familiar Electronic Batch Record (EBR) workflows, and ability to start with a focused implementation made it well suited to an academic environment where resources, budgets, and specialist expertise were limited.
Just as importantly, the project would be supported by BatchLine’s implementation and validation specialists, helping the team navigate GMP requirements while building confidence throughout the deployment.
Bringing Digital Manufacturing to Life
The implementation focused on making digital manufacturing practical.
Rather than redesigning every manufacturing process, BatchLine worked closely with the organisation to digitise existing workflows while introducing the controls required for GMP compliance.
The project included:
- Electronic Batch Record (EBR) implementation
- Risk-based Computerised System Validation (CSV)
- Digital manufacturing instructions and records
- User coaching and knowledge transfer
- GMP-compliant electronic documentation
- Progressive deployment aligned with operational readiness
From Paper Records to Trusted Data
The impact extended far beyond replacing paper.
Electronic batch records reduced manual transcription and improved manufacturing traceability. Review and approval processes became faster and more consistent. Most importantly, the organisation established a stronger foundation for data integrity which is one of the most important requirements for GMP manufacturing.
Today, BatchLine supports compliant manufacturing operations while providing a platform that can continue to grow alongside the organisation’s future programmes.
The next phase will integrate quality control (QC) activities into the same digital environment, creating an end-to-end manufacturing and quality platform that connects production data with final product release.
Looking Beyond Today
For the organisation, digital manufacturing is not the destination. It is the foundation.
Its long-term vision is to create a sustainable manufacturing ecosystem that enables collaboration between academia, biotechnology companies, and future manufacturing partners, helping innovative therapies reach patients faster without compromising quality or compliance.
As advanced therapies continue to reshape healthcare, the organisation believes practical digital manufacturing platforms will play a critical role in making these treatments more accessible, scalable, and sustainable.
Their journey demonstrates that digital transformation does not begin with technology.
It begins with the decision to build a better manufacturing foundation.
Why BatchLine?
BatchLine helps pharmaceutical, biotechnology, CDMO, medical device, and cell & gene therapy manufacturers replace paper-based processes with a modern, simple, efficient, and affordable digital manufacturing platform for GxP-compliant operations.
Purpose-built for GxP-regulated manufacturing,
BatchLine enables organisations to:
- Digitise batch records with compliant Electronic Batch Records (EBR) and Manufacturing Execution System (MES)
- Simplify validation through a risk-based approach
- Strengthen data integrity and manufacturing traceability
- Rapidly deploy cloud-based manufacturing applications
- Accelerate batch review and product release
- Scale from research and pilot manufacturing to commercial production
Editor's Note
This case study is adapted with permission from a customer success story originally published by our strategic partner, B-EN-G. To respect customer confidentiality, the organisation name and personnel identities have been anonymised.
